vs
Side-by-side financial comparison of ABVC BIOPHARMA, INC. (ABVC) and NOVO NORDISK A S (NVO). Click either name above to swap in a different company.
ABVC Biopharma Inc. is a clinical-stage biopharmaceutical enterprise focused on developing innovative therapies for unmet medical needs, with core areas including oncology, ophthalmology, and central nervous system disorders. It operates across North American and Asian markets, advancing multiple proprietary drug candidates through clinical development phases.
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $796.0K | — | ||
| Q4 24 | $2.0K | — | ||
| Q3 24 | $389.3K | — | ||
| Q2 24 | $117.1K | — | ||
| Q1 24 | $1.2K | — | ||
| Q4 23 | $2.2K | — | ||
| Q3 23 | $15.9K | — | ||
| Q2 23 | $6.1K | — |
| Q3 25 | $-2.0M | — | ||
| Q4 24 | $-731.6K | — | ||
| Q3 24 | $-394.8K | — | ||
| Q2 24 | $-942.3K | — | ||
| Q1 24 | $-2.8M | — | ||
| Q4 23 | $-383.3K | — | ||
| Q3 23 | $-3.3M | — | ||
| Q2 23 | $-2.3M | — |
| Q3 25 | 100.0% | — | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | 77.0% | — | ||
| Q4 23 | -6329.8% | — | ||
| Q3 23 | -86.4% | — | ||
| Q2 23 | -1094.6% | — |
| Q3 25 | -246.8% | — | ||
| Q4 24 | -35837.4% | — | ||
| Q3 24 | -77.7% | — | ||
| Q2 24 | -734.2% | — | ||
| Q1 24 | -235539.8% | — | ||
| Q4 23 | -23641.3% | — | ||
| Q3 23 | -13566.3% | — | ||
| Q2 23 | -35911.6% | — |
| Q3 25 | -256.6% | — | ||
| Q4 24 | -37211.3% | — | ||
| Q3 24 | -101.4% | — | ||
| Q2 24 | -804.4% | — | ||
| Q1 24 | -235203.2% | — | ||
| Q4 23 | -17705.7% | — | ||
| Q3 23 | -20885.9% | — | ||
| Q2 23 | -37052.1% | — |
| Q3 25 | $-0.09 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $-0.08 | — | ||
| Q1 24 | $-0.29 | — | ||
| Q4 23 | $0.25 | — | ||
| Q3 23 | $-0.82 | — | ||
| Q2 23 | $-0.68 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
